Intravenous immunoglobulin (IVIG [Gammagard]) did not reduce cognitive decline or preserve functional abilities in patients with mild to moderate Alzheimer disease, according to a phase 3 randomized trial.
The trial enrolled 390 patients at 45 centers across the United States and Canada. Participants received IVIG or placebo every 2 weeks for 18 months. The study results did not show a statistically significant difference in the rate of cognitive decline or functional ability for those receiving IVIG compared with placebo.
From JAMA’s Daily News Site. JAMA. 2013;310(2):132. doi:10.1001/jama.2013.8331
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: